Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Total Debt for 9 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Total Debt rose 7.79% to $28.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $28.3 million, a 7.79% increase, with the full-year FY2023 number at $28.3 million, up 7.79% from a year prior.
  • Total Debt was $28.3 million for Q4 2023 at Cartesian Therapeutics, up from $24.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $28.3 million in Q4 2023 to a low of $14.8 million in Q2 2020.
  • A 5-year average of $23.6 million and a median of $25.0 million in 2021 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: tumbled 31.16% in 2020, then soared 70.04% in 2021.
  • Cartesian Therapeutics' Total Debt stood at $18.9 million in 2019, then soared by 31.15% to $24.8 million in 2020, then grew by 3.39% to $25.6 million in 2021, then rose by 2.45% to $26.3 million in 2022, then rose by 7.79% to $28.3 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Total Debt are $28.3 million (Q4 2023), $24.0 million (Q2 2023), and $26.4 million (Q1 2023).